Company profile
Series A
Last updated:
Developing medicines to treat patients with neurological conditions
A University of Edinburgh spinout
Neurocentrx, a 2014 spinout from the University of Edinburgh, develops therapies to treat neurological conditions by providing existing approved drugs in new and improved formats for patients (through reformulation, reindication, clinical development and product in-licensing).
Neurocentrx is currently developing two oral ketamine formulations:
Keticap™ IR (Immediate Release) - an oral capsule formulation aimed at the timely release of Ketamine.
Keticap™ AD (Abuse Deterrent) - gel-like formulations that make dissolving formulations in solvents, injecting or grinding and inhaling the formulations quite difficult.
